Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company develops and commercializes proteomics technologies designed to detect and analyze protein biomarkers at very low concentrations in biological samples such as blood. Its platform combines proprietary instruments, consumables, and software to provide an end-to-end system for measuring multiple low-abundance proteins across research and potential clinical applications. The company’s technology is used in areas ranging from early-stage discovery to translational research, with an emphasis on enabling more precise and consistent protein detection.
The Fremont, CA-based company was founded in 2018 and booked $74 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol ALMR. Alamar Biosciences filed confidentially on January 9, 2026. J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel are the joint bookrunners on the deal.
